Abstract Details

Title Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis: Changes in Treatment Patterns and Opinions in a Province-Wide Study

Topic MS and Related Diseases

Presentation(s) P05 - (-)

Poster/Presentation
Number 183

Objective

Background BACKGROUND: The CCSVI hypothesis has been of great interest to MS patients. Many Albertans have travelled out-of-country for venous angioplasty.

Design/Methods DESIGN/METHODS: Initiated in July 2011, The Alberta Multiple Sclerosis Initiative is a longitudinal observational study that uses online questionnaires to collect patient-reported information about the safety, experiences, and outcomes following CCSVI treatment. All Albertans with MS have been encouraged to participate, irrespective of treatment status. Enrollment is ongoing.

Results RESULTS: This analysis included 733 participants. Mean (SD) age was 47.9 (11.2) years, 76.5% were female, and 63.8% had relapsing remitting MS; 152 participants (20.7%; 95% CI: 17.9-23.9%) reported having CCSVI treatment, beginning in March 2010. Participants were more likely to have undergone treatment in 2010 (66.4%; 95% CI: 58.3-73.9%, n=101) than in 2011 (30.9 %; 95% CI: 23.7-38.9%, n=47), even after controlling for the period of enrolment. Between January and June 2012 only four participants had CCSVI treatment (2.6%; 95% CI: 0.7-6.6%). Older age, male sex, a progressive course, and greater disability were more common in those who had CCSVI treatment.

Conclusions CONCLUSIONS: The number of participants reporting CCSVI treatment is declining. This may indicate that patients who wanted and could afford out-of-country treatment went soon after the CCSVI hypothesis was widely publicized. However, this may also reflect declining patient interest after they observed the outcomes in this earlier group of patients. The sociodemographic and clinical characteristics of participants who received CCSVI treatment will be compared to those who did not receive treatment. Factors that influenced participants' opinions for or against having CCSVI treatment will be compared over time.

Authors/Disclosures
Luanne Metz, MD (Foothills Hospital) PRESENTER	The institution of Dr. Metz has received research support from Multiple Sclerosis Society of Canada. The institution of Dr. Metz has received research support from Calgary Health Trust. The institution of Dr. Metz has received research support from Government of Alberta.
Ruth-Ann Marrie, MD, PhD (University of Manitoba)	The institution of Dr. Marrie has received research support from CIHR. The institution of Dr. Marrie has received research support from MS Canada. The institution of Dr. Marrie has received research support from National MS Society. The institution of Dr. Marrie has received research support from Crohn's and Colitis Canada. The institution of Dr. Marrie has received research support from US Department of Defense. The institution of Dr. Marrie has received research support from The Arthritis Society. The institution of Dr. Marrie has received research support from CMSC.
Katayoun Alikhani, MD (South Health Campus)	Dr. Alikhani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Apotex, Biogen, Bristol Myers Squibb, EMD Serono, Novartis, Roche, Sanofi Genzyme.
Gregg G. Blevins, MD, FRCP(C) (University of Alberta)	Dr. Blevins has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Blevins has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Hoffman La-roche. Dr. Blevins has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Blevins has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen Idec. The institution of Dr. Blevins has received research support from Novartis. Dr. Blevins has received research support from Hoffman La-Roche. The institution of Dr. Blevins has received research support from EMD Serono. Dr. Blevins has received research support from Biogen Idec. The institution of Dr. Blevins has received research support from MS society of Canada. The institution of Dr. Blevins has received research support from Canadian Institutes of Health Research .
Jacqueline I. Bakker, MD	No disclosure on file
	No disclosure on file
Nathalie Jette, MD, MSc, FRCPC, FAAN (University of Calgary)	Dr. Jette has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ILAE Epilepsia. The institution of Dr. Jette has received research support from NIH. The institution of Dr. Jette has received research support from AES.
Oksana Suchowersky, MD, FAAN (University of Alberta Hospital)	Dr. Suchowersky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Syneos/Alexion. The institution of Dr. Suchowersky has received research support from Roche. The institution of Dr. Suchowersky has received research support from Wave LifeSciences. The institution of Dr. Suchowersky has received research support from CHDI. Dr. Suchowersky has received publishing royalties from a publication relating to health care. Dr. Suchowersky has received publishing royalties from a publication relating to health care.
Mary L. Myles, MD	No disclosure on file
	No disclosure on file
	No disclosure on file
Alastair Compston, PhD, FRCP	No disclosure on file
Jamie Greenfield	No disclosure on file
Marcus W. Koch, MD, PhD (Marcus Koch)	No disclosure on file
Scott Patten, PhD (Univ of Calgary, Community Health Sciences)	Dr. Patten has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Canadian Psychiatric Association. Dr. Patten has received publishing royalties from a publication relating to health care.
Scott W. Kraft, MD	An immediate family member of Dr. Kraft has received personal compensation for serving as an employee of Bayer. An immediate family member of Dr. Kraft has received stock or an ownership interest from Bayer .
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��